2285 completed. 2285 Phase 2, 491 Phase 1, 59 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2285 | Completed 2285 |
| Phase 1 | 491 | Completed 491 |
| Phase 3 | 59 | Completed 59 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Werewolf Therapeutics, Inc. | 24 | 2025-04-21 | 2026-10-19 |
| A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients EI-1071 tablet, oral - Mild, Moderate, or Severe Alzheimer's Disease | Phase 2 | Completed | Elixiron Immunotherapeutics Inc. | 7 | 2024-12-16 | 2026-09-23 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1 - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Hutchmed | 61 | 2024-11-05 | 2026-09-24 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG Ficus septica exudate (antiseptic plant exudates), Pterocarpus indicus exudate, Curcuma longa aqueous extract - Cutaneous Ulcer Disease, Skin Sores | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 370 | 2024-10-04 | 2024-11-29 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) DZD8586 - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 59 | 2024-03-13 | 2026-08-04 |
| An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis XTMAB-16 - Pulmonary Sarcoidosis | Phase 2 | Completed | Xentria, Inc. | 31 | 2024-03-01 | 2026-10-16 |
| Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. AON-D21, Placebo - Community-acquired Pneumonia | Phase 2 | Completed | Aptarion Biotech AG | 150 | 2024-02-02 | 2026-03-18 |
| Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab Vedotin, Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Peng Liu | 30 | 2023-12-20 | 2026-10-14 |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL Hypericin, Mechlorethamine Topical Gel - Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Phase 2 | Completed | Soligenix | 10 | 2023-12-05 | 2025-08-20 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 2 | Completed | Ellen Kim, MD | 10 | 2023-08-21 | 2026-02-09 |
| Evaluating Different Doses of Orelabrutinib in MCL Orelabrutinib High dose, Orelabrutinib Low dose - Mantle Cell Lymphoma | Phase 2 | Completed | InnoCare Pharma Inc. | 40 | 2023-08-18 | 2026-06-11 |
| A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 - Chronic Lymphocytic Leukemia, COVID-19 Infection | Phase 2 | Completed | City of Hope Medical Center | 47 | 2023-08-01 | 2026-09-09 |
| Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas Chidamide - T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Completed | Zhejiang University | 44 | 2023-07-15 | 2025-12-05 |
| Janus Kinase Inhibition in Sarcoidosis Abrocitinib 200 mg - Sarcoidosis | Phase 2 | Completed | Yale University | 10 | 2023-06-01 | 2026-09-21 |
| Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease AZ-3102 (Dose 1), Placebo, AZ-3102 (Dose 2) - GM2 Gangliosidosis, Niemann-Pick Disease, Type C | Phase 2 | Completed | Azafaros B.V. | 13 | 2023-04-24 | 2026-05-14 |
| A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS)) Plonmarlimab - Hemophagocytic Lymphohistiocytoses | Phase 2 | Completed | TJ Biopharma Co., Ltd. | 18 | 2023-04-07 | 2025-06-24 |
Showing 20 of 2285. Sign in to see all of them.
Lymphoma (696) · Lymphoma, Non-Hodgkin (556) · Leukemia, Lymphocytic, Chronic, B-Cell (509) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (452) · Lymphoma, Large B-Cell, Diffuse (394) · Leukemia (384) · Lymphoma, Follicular (383) · Hodgkin Disease (355) · Lymphoma, Mantle-Cell (336) · Leukemia, Myeloid, Acute (236) · Lymphoma, B-Cell, Marginal Zone (226) · Burkitt Lymphoma (213) · Multiple Myeloma (193) · Myelodysplastic Syndromes (186) · Recurrence (181)
Hemic and Lymphatic Diseases (2284) · Immune System Diseases (2179) · Lymphoproliferative Disorders (2149) · Neoplasms by Histologic Type (2149) · Immunoproliferative Disorders (2134) · Neoplasms (2093) · Hematologic Diseases (1074) · Lymphoma (902) · Leukemia, Lymphoid (844) · Pathological Conditions, Signs and Symptoms (791) · Pathologic Processes (771) · Disease Attributes (719) · Lymphoma, Non-Hodgkin (709) · Chronic Disease (607)
Rituximab (449) · Cyclophosphamide (419) · Etoposide (206) · Vincristine (195) · Filgrastim (179) · Doxorubicin (175) · Cytarabine (168) · fludarabine phosphate (157) · Prednisone (146) · Methotrexate (145) · Peripheral Blood Stem Cell Transplantation (119) · Dexamethasone (114) · fludarabine (114) · Radiotherapy (104) · Lenalidomide (101)
M.D. Anderson Cancer Center (135) · National Cancer Institute (NCI) (132) · Memorial Sloan Kettering Cancer Center (73) · Fred Hutchinson Cancer Center (68) · Alliance for Clinical Trials in Oncology (40) · Novartis Pharmaceuticals (34) · Dana-Farber Cancer Institute (30) · Hoffmann-La Roche (28) · GlaxoSmithKline (26) · Mayo Clinic (23) · National Heart, Lung, and Blood Institute (NHLBI) (23) · Genzyme, a Sanofi Company (22) · SWOG Cancer Research Network (22) · Children's Oncology Group (20) · Fondazione Italiana Linfomi - ETS (20)
United States (1555) · France (220) · Germany (202) · Italy (197) · Canada (175) · United Kingdom (171) · Spain (122) · Australia (101) · Belgium (91) · China (79) · South Korea (74) · Poland (67) · Netherlands (63) · Japan (58) · Austria (54)
Brenda Sandmaier (9) · Craig Moskowitz, MD (9) · Tanya Trippett, MD (8)
PMID 34515338, PMID 32499241, PMID 35622074, PMID 23524640, PMID 27209293, PMID 31401903, PMID 23065508, PMID 29358183, PMID 38502198, PMID 40135712, PMID 17242396, PMID 18035553, PMID 18424759, PMID 18557726, PMID 18596230, PMID 19066739, PMID 20236866, PMID 23834234, PMID 26373676, PMID 27282998, PMID 30125215, PMID 31050355, PMID 32632956, PMID 32770353, PMID 35787017, PMID 35882475, PMID 37981564, PMID 38662147, PMID 40156952, PMID 17284531, PMID 18997171, PMID 19451441, PMID 19667400, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24224624, PMID 24862638, PMID 25381051, PMID 26182309, PMID 26813675, PMID 27750483, PMID 29437592, PMID 30575311, PMID 30957581, PMID 31023700
P30CA015704 (38), U10CA031946 (32), U10CA032102 (25), 2015 (22), 2014 (20), 2009 (17), 2016 (17), P30CA016672 (15), P30CA015083 (14), 2005 (13), P01CA018029 (13), P30CA043703 (13), 2018 (12), P30CA033572 (12), U10CA098543 (12)